Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 540

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 3
Chunk 540
---
, 2024).

    10.38
     
    Placement
    Agency Agreement, dated April 24, 2024, between INmune Bio Inc. and Maxim Group LLC (incorporated by reference to Exhibit 10.2
    to Current Report on Form 8-K filed with the SEC on April 26, 2024).

    10.39
     
    Form
    of Nonqualified Option Agreement of INmune Bio Inc. (incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed
    with the SEC on May 16, 2024).

    10.40
     
    Form
    of Incentive Stock Option Agreement of INmune Bio Inc. (incorporated by reference to Exhibit 10.2 to Current Report on Form 8-K filed
    with the SEC on May 16, 2024).

    10.41
     
    Incentive
    Stock Option Agreement between INmune Bio Inc. and Dr. Tesi, dated June 10, 2024 (incorporated by reference to Exhibit 10.1 to Current
    Report on Form 8-K filed with the SEC on June 13, 2024).

    10.42
     
    Securities
    purchase agreement to purchase common stock and warrants (incorporated by reference to Exhibit 10.1 to the Current Report on Form
    8-K filed with the SEC on September 16, 2024).

    10.43
     
    Warrant to purchase common stock (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed with the SEC on September 16, 2024).

    10.44
     
    At-the-Market Sales Agreement, dated August 9, 2024, by and among INmune Bio Inc., RBC Capital Markets, LLC and BTIG, LLC (incorporated by reference to Exhibit 1.1 to the Current Report on Form 8-K filed on August 9, 2024).

    19.1
     
    Insider Trading Policy.*

    21.1
     
    Subsidiaries.*

    23.1
     
    Consent of Marcum LLP, independent registered public accounting firm.*

    31.1
     
    Certification of principal executive officer